Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Novaccess Global Inc XSNX

Healthcare Biotechnology
NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.


OTCPK:XSNX - Post by User

Novaccess Global Inc > THEY NEED A MAJOR COMPANY TO SUPPORT THEM
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(36)
•••
Comment by virgo85on Jan 08, 2018 9:23am
85 Views
Post# 27304645

RE:RE:RE:RE:THEY NEED A MAJOR COMPANY TO SUPPORT THEM

RE:RE:RE:RE:THEY NEED A MAJOR COMPANY TO SUPPORT THEM
Peanutbudder wrote:
o.o I only entered on Friday.. don't see sessions havingthis knock down any harder... once everyone brings their money back into Cali will be looking at a 2 or 3 bagger right away... Sessions is getting any support. Still have to do more DD on these guys which patents do they hold? I really see this being beneficial to for green houses don't need power hooked up from the city just install your own on site transformer and away you go.... once a few MJ producers sign up and see savings I bet more will get on board


EXACTLY my feelings to...some money saving big mj green house contract needed to head this...to $$$
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities